演題抄録

International Session

開催概要
開催回
第55回・2017年・横浜
 

Clinical Significance of Circulating Exosomal microRNA as a Biomarker in Each Tumor Stage of Colorectal Cancer

演題番号 : IS6-4

[筆頭演者]
飯沼 久恵:1 
[共同演者]
塚本 充雄:1、田村 純子:1、八木 貴博:1、赤羽根 拓弥:1、島田 竜:1、端山 軍:1、岡本 耕一:1、土屋 剛史:1、野澤 慶次郎:1、松田 圭二:1、橋口 陽二郎:1

1:帝京大学・医学部・外科

 

Objective: We clarified the predictive and prognostic value of circulating plasma exosomal microRNA-21 (miR-21) in each TNM stage of CRC patients. Methods: MicroRNAs (miRNAs) profiling of plasma exosome, primary tumor tissues and liver metastasis tissues of the same CRC patients were examined using the microarray. For validation analysis, plasma exosome samples of 326 CRC patients (TNM stage I n=51, TNM stage II n=110, TNM stage III n=98, TNM stage IV n=67) were measured by Taqman microRNA assays. Results: In the miRNA microarray analyses, miR-21 showed the highest up-regulation in exsosomes, primary tumor tissues and liver metastasis tissues. In the exosomal samples, miR-21 showed the highest fold change (3.2 times) as compared with that of the healthy controls. Furthermore, miR-21 expression showed the highest fold-changes in the primary tumor tissues (5.2 times) and liver metastasis tissues (3.6 times) as compared with that of normal tissues adjacent to tumor tissues. Significant correlations were demonstrated between plasma exosomal miR-21 and tissue miR-21 levels in samples of same patients. As for the relationship to pathological condition, the exosomal miR-21 showed a significant association with liver metastasis and TNM stage. The overall survival rates (OS) and disease-free survival rates (DFS) of high exosomal miR-21 patients were significantly worse than those of low miR-21 patients. Exosomal miR-21 levels were an independent prognostic factor for OS and DFS in CRC patients with TNM stage II or III, and for OS in patients with TNM stage IV. Conclusion: The plasma exosomal miR-21 levels are a useful biomarker for prediction of recurrence and poor prognosis in CRC patients with TNM stage II, III or IV. In particular, miR-21 has potential for the effective selection of high-risk patients with TNM stage II in need of adjuvant chemotherapy.

キーワード

臓器別:大腸・小腸

手法別:バイオマーカー

前へ戻る